NeoImmuneTech, Inc.
A clinical-stage biopharma developing T cell-focused immuno-therapeutics for diseases.
950220 | KO
Overview
Corporate Details
- ISIN(s):
- KR8840140006
- LEI:
- Country:
- United States of America
- Address:
- 2400 Research Boulevard, Suite 250, Rockville, MD 20850, Rockville
- Website:
- https://www.neoimmunetech.com/en
Description
NeoImmuneTech, Inc. is a clinical-stage, T cell-focused biopharmaceutical company dedicated to the development of novel immuno-therapeutics. The company's lead asset is NT-I7 (efineptakin alfa), a long-acting human interleukin-7 (IL-7) fusion protein designed to amplify and reinvigorate T cells. This core technology aims to enhance the immune system's ability to eliminate cancer cells and pathogens. NT-I7 is being developed as a foundational immuno-oncology therapy for use in combination with other cancer treatments, such as checkpoint inhibitors, as well as for applications in infectious diseases. The company's research is focused on leveraging T cell amplification to address a wide range of challenging diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-03-20 00:00 |
감사보고서제출
|
Korean | 28.4 KB | ||
| 2024-03-14 00:00 |
주주총회소집결의
|
Korean | 15.1 KB | ||
| 2024-03-14 00:00 |
주주총회소집공고
|
Korean | 175.7 KB | ||
| 2024-03-14 00:00 |
주주총회집중일개최사유신고
|
Korean | 4.9 KB | ||
| 2024-02-15 00:00 |
매출액또는손익구조30%(대규모법인은15%)미만변동(자율공시)
|
Korean | 12.3 KB | ||
| 2023-12-08 00:00 |
기타경영사항(자율공시)(제10기 정기주주총회 권리주주 확정을 위한 증권예탁증권 기준일 설정 공고)
|
Korean | 4.9 KB | ||
| 2023-11-17 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.0 KB | ||
| 2023-11-14 00:00 |
분기보고서 (2023.09)
|
Korean | 1.1 MB | ||
| 2023-11-03 00:00 |
주식등의대량보유상황보고서(약식)
|
Korean | 61.0 KB | ||
| 2023-09-27 00:00 |
주식매수선택권부여에관한신고
|
Korean | 15.3 KB | ||
| 2023-08-14 00:00 |
반기보고서 (2023.06)
|
Korean | 1.0 MB | ||
| 2023-08-09 00:00 |
기업설명회(IR)개최
|
Korean | 6.8 KB | ||
| 2023-07-18 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.6 KB | ||
| 2023-07-12 00:00 |
투자판단관련주요경영사항(임상시험계획자진취하등)(NT-I7 (NIT-104 (교모세포종)) 임상 1상 시험 자진 중단)
|
Korean | 10.5 KB | ||
| 2023-07-12 00:00 |
투자판단관련주요경영사항(임상시험계획자진취하등)(NT-I7 (NIT-106 (고위험 피부암)) 임상 1b/2a상 시험 자진 중단)
|
Korean | 10.4 KB |
Automate Your Workflow. Get a real-time feed of all NeoImmuneTech, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for NeoImmuneTech, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NeoImmuneTech, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
